Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246920 · ClinicalTrials.gov registry record · Phase 3
Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients
A Phase 3 study, sponsored by Teva Pharmaceuticals USA.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,474
- Enrollment target
NCT02246920: Clinical Trial Phase 3 study, sponsored by Teva Pharmaceuticals USA.
NCT02246920 is a Phase 3 study that was terminated before completion, run by Teva Pharmaceuticals USA. The registered enrollment target is 1,474 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02246920, a Phase 3 study, was terminated before completion, sponsored by Teva Pharmaceuticals USA.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,474 participants
- Enrollment target
Study Summary
This double-blind, randomized, placebo-controlled, parallel group, multi-site study has been designed to compare the safety and efficacy of a generic Fluticasone propionate Nasal Spray, 50 mcg (Teva Pharmaceuticals USA) to the FDA Reference Listed Drug, Flonase® (fluticasone propionate) 50 mcg nasal spray (GlaxoSmithKline), in the relief of the signs and symptoms of Seasonal Allergic Rhinitis. Additionally, both the test and reference formulations will be tested for superiority against a placebo nasal spray.
Interventions
- DRUG Placebo
- DRUG Fluticasone propionate
- DRUG Flonase®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,474 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2014-07-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02246920
The ClinicalTrials.gov registry entry for NCT02246920 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02246920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02246920 about?
NCT02246920 is a clinical study titled "Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients". This double-blind, randomized, placebo-controlled, parallel group, multi-site study has been designed to compare the safety and efficacy of a generic Fluticasone propionate Nasal Spray, 50 mcg (Teva Pharmaceuticals USA) to the FDA Reference Listed Drug, Flonase® (fluticasone propionate) 50 mcg nasal...
What is the current status of trial NCT02246920?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,474 participants. The study started on 2014-03-01. Estimated completion is 2014-07-14.
What interventions are being tested in trial NCT02246920?
The interventions under investigation include: Placebo (DRUG), Fluticasone propionate (DRUG), Flonase® (DRUG).
Who is sponsoring clinical trial NCT02246920?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.